Skip to Content
Merck
  • Rebound insomnia induced by abrupt withdrawal of hypnotics in sleep-disturbed rats.

Rebound insomnia induced by abrupt withdrawal of hypnotics in sleep-disturbed rats.

European journal of pharmacology (2008-09-16)
Masahiro Hirase, Takayuki Ishida, Chiaki Kamei
ABSTRACT

The present study was performed to examine whether or not rebound insomnia is caused by an abrupt withdrawal of benzodiazepine hypnotics and tandospirone in rats. Etizolam and triazolam caused a significant shortening of sleep latency, increase in non-REM sleep time, and decrease in wake time in a dose-dependent manner. Etizolam and triazolam caused a significant shortening of sleep latency during drug administration (for 7 days), whereas a significant prolongation of sleep latency was observed by the abrupt withdrawal of these drugs. Tandospirone caused a shortening of sleep latency, whereas no effect was observed on non-REM sleep time and wake time during drug administration (for 7 days). On the other hand, tandospirone showed no significant effect on sleep latency through its abrupt withdrawal, differing from etizolam and triazolam. From these findings, a rebound phenomenon in terms of sleep latency was confirmed with etizolam and triazolam in rats. Furthermore, the 5-HT(1A) agonist, tandospirone, caused no rebound phenomenon regarding sleep latency in rats.

MATERIALS
Product Number
Brand
Product Description

Supelco
Etizolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®